AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00741988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.
Study NCT00741988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.
Study NCT01400750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral ciprofloxacin plus inhaled colistin
Description: oral ciprofloxacin (30mg/kg/day divided in 2 doses) for 3 months (CC) plus inhaled colistimethate sodium(Colistineb® 2x2 mill U daily)
Study NCT01400750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOBI
Description: tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days
Study NCT00215306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHARITÉ Artificial Disc
Study NCT00215306 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Interbody Fusion with BAK Cage
Study NCT00117988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Study NCT02444013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Study NCT02444013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03517579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Collar Therapy Indicator (COTI)
Description: Study Device; The CoTI has 3 components;~* A collar unit: a gamma detector wrapped around a body part-neck in this case and contains a scintillating crystal and a silicon photomultiplier. The photon pulse signal is then converted to digital signals (measuring the counts per second). Usually two detectors are placed in specified positions.~* A cable that connects the collar unit to the Control Unit~* A control unit that collects the signals and transmits it wirelessly to a hand-held computer tablet.~Two types of collar devices will be used: the lower activity and the medium activity~1. Lower activity collar for patients with Graves' disease as well as diagnostic I-123 scan in thyroid cancer patients. These patients typically receive 0.2-1.2 m Ci of I-123/I-131.~2. Medium activity collar for Patients with thyroid cancer after 131-I ablation, for which patients typically receive 30-100 mci of I-131.
Study NCT03338218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volulyte 6%
Description: Solution for infusion
Study NCT03338218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ionolyte
Description: Solution for infusion
Study NCT04344405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid Drug
Description: control
Study NCT02580487 — intervention group
Intervention type: PROCEDURE
Intervention: appendicectomy
Description: Appendix was removed either laparoscopically or open surgery
Study NCT03830008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management Plus
Description: PM+ is a new, brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
Study NCT03136705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide
Description: Nicotinamide tablet
Study NCT03136705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate
Description: Lanthanum Carbonate tablet
Study NCT03136705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate Placebo
Description: Sugar pill manufactured to look like Lanthanum Carbonate tablet
Study NCT03136705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lanthanum Carbonate Placebo
Description: Sugar pill manufactured to look like Lanthanum Carbonate tablet
Study NCT03136705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Placebo
Description: Sugar pill manufactured to look like Nicotinamide tablet
Study NCT03136705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotinamide Placebo
Description: Sugar pill manufactured to look like Nicotinamide tablet
Study NCT03430245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VelaShape III
Description: The VelaShape III device combines controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with vacuum.
Study NCT03430245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UltraShape Power
Description: The UltraShape Power device uses focused ultrasound energy for lipolysis (breakdown of fat) via a non-thermal mechanism of action.
Study NCT03965988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA
Description: Docosahexaenoic acid
Study NCT03854474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Given PO
Study NCT04074135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Gallium DOTATATE
Description: 68-Gallium DOTATATE, to be used in yearly PET/CT research scans
Study NCT03374306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine (0.01%)
Description: tropical application
Study NCT03374306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tear
Description: tropical application
Study NCT01370551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estriol 0.03 mg, lyophylized lactobacillus
Description: Vaginal tablet with lyophilised lactobacilli and 0.03 mg estriol; Once daily for 28 days then 3 times per week for 8 weeks;
Study NCT04083378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation Therapy
Description: Undergo standard of care ablation
Study NCT04083378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation Therapy
Description: Undergo standard of care ablation
Study NCT04083378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image-Guided Therapy
Description: Undergo software-aided imaging (Morfeus)
Study NCT04083378 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04083378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04083378 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04083378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02413970 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Inspire® UAS System
Description: This is a single-arm study; all participants will be implanted with the Inspire® UAS System, which is a permanent, implantable therapy that consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the study subject receives a remote control to activate the therapy.
Study NCT03996291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Pharmaceutical form: Film coated tablet Route of administration: Oral
Study NCT03461991 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrahigh resolution Spectral Domain OCT
Description: A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed.
Study NCT01172782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: 2.5, 5, 10 ug of hydromorphone, intrathecal injection, single injection. duration of intrathecal injection are not fully studied.
Study NCT01172782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydromorphone
Description: 2.5, 5, 10 ug of hydromorphone, intrathecal injection, single injection. duration of intrathecal injection are not fully studied.
Study NCT04241276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: 45 mg/m2 orally (in two divided doses) from days 1 to 15 of each cycle
Study NCT04241276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000mg/m2 IV on days 1, 8 and 15 of a 28 day cycle
Study NCT04241276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 IV on days 1, 8 and 15 of a 28 day cycle
Study NCT04241276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: 125mg/m2 IV on days 1, 8 and 15 of a 28 day cycle
Study NCT04241276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 125mg/m2 IV on days 1, 8 and 15 of a 28 day cycle
Study NCT02056769 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT Perfusion
Description: Quantitative CT Perfusion imaging
Study NCT01561469 — intervention group
Intervention type: DRUG
Intervention: Linezolid
Description: Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with linezolid according to routine medical care.
Study NCT01561469 — intervention group
Intervention type: DRUG
Intervention: Vancomycin
Description: Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with vancomycin according to routine medical care.
Study NCT02314195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selective serotonin re-uptake inhibitor
Description: A medication of selective serotonin re-uptake inhibitor (SSRI) family, Behavioral. The type and dosage of the medication was decided by the treating psychiatrist.
Study NCT02314195 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy for obsessive compulsive disorder carried out by a psychologist.
Study NCT02314195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music therapy
Description: 12 sessions of 30-minute individual-based receptive music therapy, supervised by the treating psychiatrist.
Study NCT04194827 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Adalimumab serum trough concentration
Description: Dose reduction based on adalimumab serum trough concentration
Study NCT04194827 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Disease activity
Description: Dose reduction based on adalimumab diseas activity
Study NCT04194827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab
Study NCT04194827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab
Study NCT03207347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Patients will take 300 mg of niraparib orally once daily each day of a 28 day cycle.
Study NCT01761149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)
Study NCT01761149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)
Study NCT01558167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine, Rituximab, Lenalidomide
Description: Bendamustine: 50 mg/m2, i.v., day 1+2~Rituximab: Cycle 1: 375 mg/m2, i.v. day 0; Cycle 2-6: 500mg/m2, i.v., day 1~Lenalidomide:~* Dose level 1: Cycle 1-6: 2,5mg p.o., d1-28~* Dose level 2: Cycle 1: 2,5mg p.o., d1-28; Cycle 2-6: 5mg p.o., d1-28~* Dose level 3: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3-6: 10 mg p.o., d1-28~* Dose level 4: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3: 10 mg p.o.,d1-28, Cycle 4-6: 15 mg p.o.,d1-28~* Dose level 5: maximal tolerated dose
Study NCT00572559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: 1 gram IV every 12 hours for 7 to 14 days
Study NCT00572559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: 600 mg every 12 hours (intravenously \[IV\] for a minimum of the first 4 days followed by a switch to oral if tolerated by patient) for a total duration of 7 to 14 days
Study NCT00469118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRX9000™
Description: Nonsurgical spinal decompression
Study NCT02814266 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: difficult intubation
Description: Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.
Study NCT02814266 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: easy intubation
Description: Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.
Study NCT00925730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Study NCT03317639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour Change Wheel model guided intervention
Description: Interventions are developed on a psychological model, the Behaviour Change Wheel (BCW) .The fundamental of BCW consists of three essential elements: capability, motivation, and opportunity. Improving individual's capability, providing motivation, and increasing opportunities are goals of behaviour change intervention. To achieve the goals, 9 intervention components have been proposed in the BCW framework, and 6 components will be used in current study.
Study NCT03904199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Participants will receive long-acting insulin and/or rapid-acting insulin per protocol
Study NCT03904199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participants will receive long-acting insulin and/or rapid-acting insulin per protocol
Study NCT03321955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziconotide 100 MCG(microgram)/ML Intrathecal Solution
Description: Initial dose at time of the implant will be 1.2 mcg/day with dose increases of no more the .4 mcg/day planned for 3, 6, 8, 9, 10, 12 weeks and 4, 5, 6 and 12 months.
Study NCT03321955 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing
Description: Quantitative sensory testing will be done using different types of sensory stimulation to objectively quantify sensation and pain tolerance. VonFrey fibers of various widths are used to detect sensation, a Neuropen pin prick iutilized to detect pain, along with a tuning fork to measure vibrationand a pressure guage to measure pressure felt on the skin. Cold/hot sensation is tested with Medoc Pathway system to quantitatively measure the temperature felt by patients to be done at baseline, 6 months and 12 months,
Study NCT02371304 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy
Description: Patients will receive capecitabine 825 mg/m2 twice a day for 5 weeks only on weekdays. This will be combined with 1.8 Gy in 25 fractions with a limited dose only on the mesorectum
Study NCT00643279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chronicle Implantable Hemodynamic Monitor
Description: Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead. The implantable hemodynamic monitoring device captures intracardiac hemodynamic information about the patient including trended right ventricular (RV) and estimated pulmonary arterial (PA) pressures, heart rate and activity data. The IHM device does not provide therapy, but rather provides intracardiac diagnostic information about the patient which the physician can utilize to manage the patient and the patients heart failure.
Study NCT00643279 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead, but physician and patient access to the intracardiac information provided by the device is restricted until the end of the randomized period of the study, at 6 months. Patients and patients heart failure are managed conventionally per standard of care.
Study NCT04029779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: I-PRF
Description: Local anaesthesia was administered and mucoperiosteal flap was reflected. Atraumatic tooth extraction was performed. Socket was curetted to remove the granulation tissue present in the socket with the help of curettes. The socket was well irrigated with saline. Implant osteotomies wasl performed with sequential drilling with standardized drills.I-PRF was freshly prepared 600rpm for 7 min(50g). 1ml of the i-PRF was applied in to the osteotomy site and the implant surface will be thoroughly coated followed by placing of the implant. The surgical site was thoroughly irrigated and debrided. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
Study NCT01811420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemomechanical Caries Removal
Description: Chemomechanical Caries Removal Using A Papain-Based Gel
Study NCT01811420 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method
Description: Dental caries removal using rotatory instrument
Study NCT02410187 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 10 Gy x 3 - 20 Gy x 3 (BED 60Gy-180 Gy) or 8 Gy x 4 - 17 Gy x 4 (BED 58-184 Gy)
Study NCT02410187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: systemic therapy (chemotherapy, hormon therapy, target therapy etc)
Description: Physicians can choose all the options available chemotherapy, hormon therapy, target therapy etc.~Use of chemotherapy schemes containing potent enhancers of radiation damage (e.g. gemcitabine,adriamycin) are discouraged within the first month after SBRT.
Study NCT02410187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: systemic therapy (chemotherapy, hormon therapy, target therapy etc)
Description: Physicians can choose all the options available chemotherapy, hormon therapy, target therapy etc.~Use of chemotherapy schemes containing potent enhancers of radiation damage (e.g. gemcitabine,adriamycin) are discouraged within the first month after SBRT.
Study NCT02410187 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: palliative RT
Description: fraction size of RT = \< 3 Gy
Study NCT04183712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and oxaliplatin.
Description: GEMOX Conventional chemotherapy:gemcitabine and oxaliplatin.
Study NCT04183712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine and oxaliplatin.
Description: GEMOX Conventional chemotherapy:gemcitabine and oxaliplatin.
Study NCT04183712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Target therapy Drug: afatinib
Study NCT02371304 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Additional TME surgery
Study NCT02371304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT03321955 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum markers: Interleukin-1, Interleukin-6, and tumor necrosis factor
Description: Increases in these biomarkers indicate nerve pain as they are released from macrophages in patients with damaged nerves.
Study NCT00846313 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual dietary counseling.
Description: Dietary advice based on individual requirement and symptom burden. Dietary intervention may be dietary advice, energy rich foods and drinks, oral nutritional supplements, appetite stimulation with Megestrol Acetate, enteral or parenteral nutrition.
Study NCT06369090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical impedance tomography (EIT)
Description: Non-invasive, radiation-free bedside lung monitoring using small alternating currents with no known side effects.
Study NCT03872869 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip school or Tai CHi for arthritis
Description: Eighty-nine individuals were randomized to one of the three intervention groups 30 individuals to Tai Chi,30 individuals to Hip School and 29 individuals to the control group
Study NCT00691301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin as an IV infusion at less than 1 mg/min over less than 4 hours at a dose of
Study NCT00691301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Study NCT02364492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAG-TN3 + AS15